DrugPatentWatch Database Preview
Peramivir - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic sources for peramivir and what is the scope of freedom to operate?
Peramivir
is the generic ingredient in one branded drug marketed by Biocryst and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Peramivir has sixty-three patent family members in twenty-eight countries.
There is one drug master file entry for peramivir. One supplier is listed for this compound.
Summary for peramivir
| International Patents: | 63 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 57 |
| Clinical Trials: | 15 |
| Patent Applications: | 57 |
| DailyMed Link: | peramivir at DailyMed |
Recent Clinical Trials for peramivir
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hoffmann-La Roche | Phase 3 |
| Department of Health and Human Services | Phase 4 |
| Johns Hopkins University | Phase 4 |
Synonyms for peramivir
| (-)-(1S,2S,3R,4R)-3-[(1S)-1-(Acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentanecarboxylic Acid |
| (+/-)-Peramivir |
| (1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino)-2-hydroxycyclopentane |
| (1S,2S,3R,4R)-3-((S)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentane-1-carboxylic acid |
| (1S,2S,3R,4R)-3-((S)-1-Acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid |
| (1S,2S,3R,4R)-3-(1-acetaMido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid (Peramivir) |
| (1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentanecarboxylic acid |
| (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid |
| (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic acid |
| (1S,2S,3R,4R)-4-carbamimidamido-3-[(1S)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid |
| (1S,2S,3S,4R)-3-((S)-1-acetamido-2-ethylbutyl)-4-((diaminomethylene)amino)-2-hydroxycyclopentane-1-carboxylic acid |
| (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid |
| 229614-55-5 |
| 229614-55-5,330600-85-6,1041434-82-5(3H2O) |
| 229614-56-6 |
| 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID |
| 3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid |
| 3(R)-[1(S)-Acetamido-2-ethylbutyl]-4(R)-guanidino-2(S)-hydroxycyclopentane-1(S)-carboxylic acid |
| 330600-85-6 |
| 600P856 |
| 9ZS94HQO3B |
| AB01566838_01 |
| AB2000310 |
| ABP000969 |
| AC-22715 |
| AC1L4BWX |
| AJ-47581 |
| AK-48380 |
| AKOS016007760 |
| API0004841 |
| AX8147150 |
| BCPP000117 |
| BCX 1812 |
| BCX-1812 |
| BCX1812 |
| BCZ |
| BDBM50181441 |
| BDBM5024 |
| CHEBI:85202 |
| CHEMBL139367 |
| CP0131 |
| CS-0638 |
| Cyclopentanecarboxylic acid, 3-((1R)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1R,2R,3S,4S)-rel- |
| Cyclopentanecarboxylic acid, 3-((1S)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1S,2S,3R,4R)- |
| Cyclopentanecarboxylic acid, 3-[(1S)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1S,2S,3R,4R)- |
| DB06614 |
| HY-17015A |
| PeramiFlu |
| Peramivir [USAN:INN] |
| Peramivir, (+/-)- |
| Rapiacta |
| RAPIVAB |
| RL02720 |
| RL03191 |
| RWJ 270201 |
| RWJ-270201 |
| RWJ270201 |
| S-021812 |
| SCHEMBL12795462 |
| SCHEMBL744373 |
| ST2402123 |
| UNII-9ZS94HQO3B |
| ZINC3981610 |
US Patents and Regulatory Information for peramivir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for peramivir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | Start Trial | Start Trial |
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for peramivir
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2009533428 | Start Trial |
| South Korea | 20180024027 | Start Trial |
| China | 101420948 | Start Trial |
| Japan | 2015180695 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
